Personalis, Inc. Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter filing; quarterly results are not separately provided in the supplied text.
Business Context
Personalis develops cancer genomic tests, liquid-biopsy and tumor-profiling products, sequencing services, and analytics for pharmaceutical, diagnostics, academic, government, and clinical customers. Principal products include NeXT Personal, NeXT Personal Dx, NeXT Dx, and ImmunoID NeXT. The company operates one reportable segment and performs testing primarily through its CLIA-certified, CAP-accredited Fremont, California laboratory.
- Revenue mix by geography: United States 90%, Europe 8%, and Asia-Pacific 2%.
- Clinical diagnostics revenue remained insignificant during the periods presented.
- Customer concentration remained high: Natera represented 43% of 2023 revenue, VA MVP 13%, and the top five customers 74%.
Financial Performance and Key Metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $73.5 million | $65.0 million | +13% |
| Gross profit | $18.2 million | $13.4 million | +36% |
| Gross margin | 24.8% | 20.5% | +4.3 percentage points |
| Loss from operations | $(109.9) million | $(115.5) million | Improved $5.6 million |
| Operating margin | (149.6%) | (177.6%) | Improved |
| Net loss | $(108.3) million | $(113.3) million | Improved $5.0 million |
| Net loss per share | $(2.25) | $(2.48) | Improved |
| Net cash used in operating activities | $(56.3) million | $(70.2) million | Improved $14.0 million |
- Pharma tests and services revenue increased 8% to $31.9 million.
- Enterprise sales increased 19% to $31.7 million, driven by higher Natera sample volumes; Natera sample volume increased more than 55%, but pricing declined.
- Population sequencing revenue increased 11% to $9.4 million despite an approximately 50% reduction in selling prices, reflecting higher sample volumes.
- Cost of revenue increased 7% to $55.3 million, below the 13% revenue growth rate.
- Research and development expense was essentially flat at $64.8 million. Selling, general and administrative expense declined 22% to $49.7 million.
- Net loss included $5.6 million of noncash Menlo Park lease impairment and $8.1 million of restructuring and other charges. Other expense included approximately $4.0 million related to the fair-value remeasurement and initial accounting for Tempus warrants.
Liquidity, Debt, and Capital Resources
- Cash and cash equivalents plus short-term investments were $114.2 million at December 31, 2023, versus $167.7 million at December 31, 2022.
- Cash and cash equivalents were $57.0 million; short-term investments were $57.2 million.
- Working capital was $99.5 million, down from $166.6 million.
- Total debt was $2.9 million, including $1.6 million classified as current. The filing also reports $10.0 million of Tempus warrant liabilities, which are not debt but may result in equity dilution or cash settlement obligations depending on the terms.
- Operating lease liabilities totaled $46.1 million at present value; undiscounted future operating lease payments totaled $78.6 million.
- Capital expenditures were $10.9 million in 2023, down from $49.9 million in 2022. Management expects approximately $1 million of capital expenditures in 2024 and $4 million to $6 million annually in 2025 and 2026.
- Management states that existing cash, investments, and anticipated operating cash flows are expected to fund requirements for at least the next 12 months, but additional capital may be required if demand or cash flow falls short.
- The company may sell up to $50.0 million of common stock through its ATM facility; it sold $3.5 million of stock under the facility in 2023.
Material Changes Versus 2022
- Revenue growth resumed, primarily from enterprise and pharmaceutical customers, after total revenue declined 24% in 2022.
- Operating cash burn improved by $14.0 million, primarily due to lower operating spending, workforce reductions, customer deposits, and working-capital management.
- Two workforce reductions and the closure of China operations reduced headcount by nearly 50% from 2022 levels and are expected to produce approximately $35 million of annual cost savings.
- The company completed the move of laboratory operations to Fremont and began marketing the former Menlo Park facility for sublease, resulting in a $5.6 million impairment charge.
- Natera agreement minimum-volume commitments were extended through 2024. Management expects 2024 Natera revenue to decline because of lower pricing and a lower-cost exome offering.
- In November 2023, Personalis entered into a commercialization and reference laboratory agreement with Tempus. Personalis received $6 million and issued warrants for up to 9.2 million shares at exercise prices of $1.50 and $2.50 per share.
Outlook, Commentary, Risks, and Unusual Items
- Management is focused on expanding adoption of oncology products, generating clinical evidence in breast cancer, lung cancer, and immunotherapy monitoring, and obtaining reimbursement coverage.
- Personalis received a final Medicare coverage determination for NeXT Dx in January 2024, retroactive to August 29, 2023. Management plans to seek Medicare reimbursement for NeXT Personal Dx after publication of supporting clinical evidence.
- Tempus is expected to commercialize NeXT Personal Dx beginning in 2024 through its larger sales force. The agreement includes development milestones, potential fees of up to $12 million, exclusivity through December 31, 2027 subject to exceptions, and potential refund or termination rights if milestones are not achieved.
- The company expects research and development and selling, general and administrative spending to remain lower following the workforce reductions, while cost of revenue may rise with higher sample volumes.
- Major risks include continued substantial losses, reliance on Natera and VA MVP, uncertain clinical adoption and reimbursement, possible FDA regulation of laboratory-developed tests, dependence on Illumina as a key supplier, cybersecurity and data-privacy exposure, and the need for additional financing.
- Personalis is pursuing patent litigation against Foresight Diagnostics. The cases were consolidated and stayed in January 2024 pending inter partes review proceedings. The filing states that the outcome and financial impact cannot currently be predicted.
- The company’s management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2023. As a non-accelerated filer, Personalis was not required to obtain an external auditor attestation on internal control effectiveness.
Most Important Facts to Verify
- Whether Natera volumes and pricing, including the planned lower-cost offering, cause the expected 2024 revenue decline and how much capacity remains available for other customers.
- Progress toward Tempus clinical validation milestones, commercialization activity, potential milestone payments, and the effect of the warrants on dilution and future earnings.
- Whether the company can sustain annual cash savings of approximately $35 million and reduce operating cash burn without impairing product development or customer service.
- The final regulatory treatment of laboratory-developed tests and whether Personalis will need FDA clearance or PMA approval for any products.
- The scope, timing, and reimbursement rates associated with Medicare coverage for NeXT Dx and any future coverage for NeXT Personal Dx.
- Cash runway under current operating assumptions, the potential use of the $50 million ATM facility, and the risk of future equity dilution.
- The outcome and potential costs of the Foresight patent litigation and inter partes review proceedings.
- Sublease prospects for the Menlo Park facility and the potential effect on future lease-related cash costs.